Risk of Recurrence in Early Breast Cancer: Evidence, Escalation, Applicability in Australia and Ongoing Uncertainty

This live, interactive webinar will bring together Professor Elgene Lim and Professor Peter Schmid to explore risk of recurrence in early breast cancer. Through expert discussion, the session will examine how recurrence risk is defined, how current adjuvant escalation trial data can be interpreted, and where uncertainty remains in clinical practice.

Drawing on international and local perspectives, the webinar will consider biological heterogeneity of risk, the relevance of trial eligibility criteria to real world populations, and key factors that influence interpretation of benefit and treatment burden.

WHEN: Tuesday, 9 June 2026 7:30-8:30 pm AEST

Agenda

07:30 07:35 PM

Welcome

07:35 07:55 PM

Recurrence Risk and treatment escalation

07:55 08:15 PM

Interpreting applicability to Australian clinical practice

08:15 08:30 PM

Moderated live Q&A

08:30 08:30 PM

Meeting close

Speakers

prof

Peter

Schmid

Professor of Cancer Medicine; Director ,

Barts Breast Cancer Centre, London, UK

prof

Elgene

Lim

Head of breast cancer services ,

The Kinghorn Cancer Centre, St Vincent’s Hospital, Sydney, AU

First Name

Last Name

Mobile

Hospital/Practice/Institution

Profession

AHPRA Number

I confirm that I am a current practicing healthcare practitioner in Australia

I agree to the terms of use and data privacy conditions

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Risk of Recurrence in Early Breast Cancer: Evidence, Escalation, Applicability in Australia and Ongoing Uncertainty

Risk of Recurrence in Early Breast Cancer: Evidence, Escalation

Tags